Few inventions in science and medicine have had such a profound effect on human health as the discovery and subsequent development of antibiotics. Following their introduction during World War II the incidence of many dreaded infectious diseases such as diphtheria, pneumonia, syphilis, and tuberculosis fell dramatically.
However all is not well with the antibiotics story. The bacterial pathogens are fighting back and antibiotic resistance is increasing at an exponential rate, rendering classic drugs such as penicillin and streptomycin increasingly ineffective. Some 5,000 Australians and 100,000 Americans each year die from antibiotic resistant infections, prompting a frantic search for new antibiotics or other antibacterial treatments.
Special Phage Services (SPS), the operational subsidiary of Special Phage Holdings Pty Ltd (SPH) was established in 2004 to address the rapidly growing threat posed by these antibiotic-resistant infections.
Taking advantage of a long-forgotten means of combating bacterial infection known as bacteriophage or phage therapy, the company is developing a portfolio of anti-bacterial products against antibiotic-resistant infections such as MRSA (“Golden Staph), MRPA ( multi-resistant Pseudomonas aeruginosa) and VRE (vancomycin-resistant enterococci).
Want to know more about Special Phage Services? Feel free to contact us today.